Wednesday, October 3

6:00 – 7:00pm: Early Career/Trainee Networking Reception with NANETS Leadership

Thursday, October 4

7:30 – 8:30am: Breakfast

8:00 – 10:00am: Allied Health Program 1

  • Welcome and Exploration of NET Clinics - Bonnie Bennett, BSN, RN, University of Pennsylvania
  • Surgical Options for NETs - Alicia Yee
  • Systemic Options for NETs - Robyn Silberman, NP, Stanford

8:30 – 10:00am: Early Career Program 1

  • ENETS Young Investigator Forum
    • The Effect of Temozolomide on Pancreatic Neuroendocrine Tumors in Vitro and Role of MGMT and MMR System in Temozolomide Resistance - Anela Blazevic, MD, Erasmus Medical Center
    •  Epigenetic Changes in DAXX and/or ATRX Negative Pancreatic Neuro-Endocrine Tumors - Annuziata Di Domenico, PhD Student, University of Bern
    • Genetic Analysis Identifies Subgroups of Small Well-Differentiated Pancreatic Neuroendocrine Tumors with Different Risk for Liver Metastases - Antonia Pea, MD, University of Verona
  • Building an Independent Basic Science Research Program - James Bibb, PhD, University of Alabama Birmingham
  • Building an Independent Health Services Research Program - Simron Singh, MD, MPH, FRCPC, Sunnybrook Health Sciences Centre

10:00 – 10:30am: Break

10:30 am – 12:30pm: Allied Health Program 2

  • Oral Med NET Clinic - Alia Thawer, BSc, BScPharm, PharmD, Rph, Sunnybrook Health Sciences Centre
  • NET Research Project: Creating a Safety Monitoring Protocol for SSAs - Anna Jung, PharmD, BCPS, University of Pennsylvania
  • Hormones in Functional NETs - Lauren Fishbein, MD, PhD, University of Colorado 

10:30 am – 12:30pm: Early Career Program 2

  • NANETS Young Investigator Forum
    • Enhancing Efficacy of PRRT for Neuroendocrine Tumors by Combining with Everolimus and Histone Deacetylase Inhibitors - Dongyoul Lee, BS, MS, Doctoral Student, University of Iowa
    • Incidental Histological Diagnosis of Small Pancreatic Neuroendocrine Tumors: Are We Underestimating Their Incidence? - Valentina Andreasi, San Raffaele Scientific Institute, “Vita-Salute” University
    • Practical Evaluation of Tumor Number-Volume Distribution Predicts Liver-specific Progression-free Survival after Surgery for Neuroendocrine Tumor Liver Metastases - Yosuke Kasai, MD, PhD, University of California, San Francisco
  • Building Multi-Institutional Collaborations - Lauren Fishbein, MD, PhD, University of Colorado
  • Work-Life Balance - Pamela Kunz, MD, Stanford Cancer Center
  • Designing and Running a Clinical Trial - Marianne Pavel, MD, Charite - Universitatsmedizin Berlin
  • Strategies for Success: Altruism, Failure, and Being a Good Mentee - Michale Soulen, MD, University of Pennsylvania

12:30 – 2:00pm: Lunch Symposium presented by Medscape Education

2:00 – 4:00 pm: Allied Health Program 3

  • Development of a PRRT Program - Anita Piano, MSN, University of California, Los Angeles 
  • Caring for the PRRT Patient - Shelia Lindsay, MS, NP, University of California, San Francisco
  • Panel Discussion with Anita Piano, Shelia Lindsay, and Josh Mailman, MBA, NorCal Carcinet

2:00 – 3:00pm: Clinical Management 1 - Controversies in Locoregional Management of NETs

  • Ileum NETs - Rodney Pommier, MD, Oregon Health and Science University
  • Pancreatic NETs - James Howe, MD, University of Iowa
  • Embolotherapies for Liver Metastases: Are They Really Equal? - Khashayar Farsad, MD, PhD, Oregon Health and Science University

3:00 – 4:00pm: NANETS - SNMMI Symposium

  • NET Imaging: The Role of CT, MRI and PET - Shana Elman, MD, University of Washington Medical Center
  • PRRT Guidelines - Lisa Bodei, MD, PhD, Memorial Sloan Kettering Cancer Center
  • Future Directions for PRRT - Rodney Hicks, MB BS (Hons), MD, FRACP, FAHMS, Peter Maccullum Cancer Centre

4:00 – 4:20pm: Break

4:20 – 5:20pm: Allied Health Program 4 – NET Research

  • Role of Integrative Oncology in Neuroendocrine Tumors - Kathi Sanders, ARNP-BC, MPH, Seattle Cancer Care Alliance
  • Nutritional Considerations in Patients with Neuroendocrine Tumors - Kate Ueland, MS, RD, Seattle Cancer Care Alliance

4:20 – 5:20pm: Tumor Board 1 - Optimal Sequence of Therapies for Potentially Resectable Disease

  • Interventional Radiology Panel: Lisa Bodei, MD, PhD, Memorial Sloan Kettering Cancer Center; Nicholas Fidelman, MD, University of California, San Francisco; Thomas Hope, MD, University of California San Francisco; and Michael Soulen, MD, University of Pennsylvania 
  • Surgery Panel: James Park, MD, University of Washington; Rodney Pommier, MD, Oregon Health & Science Center; Sushanth Reddy, MD, University of Alabama Birmingham Medical Center; and Flavio Rocha, MD, Virgina Mason Medical Center

5:30 – 6:30pm: Poster Session Reception

7:00pm: Industry Supported Dinner Symposium

Friday, October 5

7:30 – 8:00pm: Breakfast

8:00 – 9:00am: Clinical Management 2 - Hot Topics in NETs

  • External Beam Radiotherapy in NETS: Have We Reached Full Potential? - Sten Myerhaug, MD, FRCPC, Sunnybrook Health Sciences Centre Odette Cancer Center
  • Immunotherapy in NETs: Is There a Future? - Robert Ramirez, DO, FACP, Ochsner Medical Center
  • Introduction of the Well Differentiated G3 NET - Guido Rindi, MD, PhD, Universita Cattolica del Sacro Cuore
  • Debate: G3 Well Differentiated NET: What is the Best Treatment to Start With? Targeted vs. Cytotoxic - Jennifer Chan, MD, MPH, Dana-Farber Cancer Insitute and Diane Reidy-Lagunes, MD, Memorial Sloan Kettering Cancer Center

9:00 – 10:00am: Research Keynote 

  • The Molecular Pathogenesis of Neuroendocrine Lung Cancers With Translation to the Clinic - John Minna, MD, UT Southwestern

10:00 – 10:30am: Break

10:30 – 11:30am: NET Care Around the World: Sequencing, Integration & Other Challenges

  • NETs in the NHS - Martyn Caplin, BSc Hons, DM, FRCP, Royal Free Hospital, United Kingdom
  • NETs in the EU - Wouter de Herder, MD, PhD, Erasmus Medical Center, Netherlands
  • NETs in India - Shailesh Shrikhande, MBBS, MS, MD, FRCS, Tata Memorial Hospital
  • NETs in Canada - Rachel Goodwin, MD FRCPC, The Ottawa Hospital Cancer Center

11:30am – 12:30pm: Featured Abstracts 1 - Basic/Translational Abstracts

  • Pten Loss Cooperates with MEN1 Loss to Accelerate Tumorigenesis of Neuroendocrine Tumors - Eugenia Xu, PhD, Rutgers Cancer Institute of New Jersey
  • Integrated CDK5 - AMPK phosphorylation network in Pheochromocytoma - Priyanka Gupta, PhD, University of Alabama at Birmingham
  • A RABL6A-PP2A-AKT Pathway Drives Pancreatic Neuroendocrine Tumor Growth - Shaik Amjad Umesalma, PhD, University of Iowa
  • Rational design of a Combination Therapy for MTC and Evaluation of an Imaging Biomarker for Prediction of Treatment Response - Karine Pozo, PHD, The University of Texas Southwestern Medical Center
  • Genomic Profiling of Extrapulmonary High-Grade Neuroendocrine Carcinomas (EP-NEC) Reveals “Actionable” Mutations - Julia Whitman, MSc, MA, University of Caifornia, San Francisco
  • Coupled Diagnostic-Therapeutic Regimen for Neuroendocrine Cancer - Angela Carter, PhD, University of Alabama at Birmingham

12:30 – 2:00pm: Industry Supported Lunch Symposium

2:00 – 3:00pm: Clinical Management 3 - Uncommon NETs

  • A Poster Child for Cancer Metabolism - Hans Ghayee, DO, University of Florida College of Medicine
  • Merkel Cell: Current & Future Therapy - Kelly Paulson, MD, PhD, UW Medical Center at Lake Union
  • 20 Years of MENIN - Sunita Agarwal, PhD, National Institutes of Health
  • Pituitary Tumors and pNETs: Siblings of Cousins? - Anthony Heaney, MD, University of California, Los Angeles

3:00 – 4:00pm: NANETS - SIO Symposium

  • Emboman vs. BetaGal: Battle of the Radiologists
  • PRRT Should be 1st-line for Liver-Dominant Metastasis - Lisa Bodei, MD, PhD, Memorial Sloan Kettering Cancer Center
  • Embolization Remains the Best Option for Liver-Dominant Metastasis - Nicholas Fidelman, MD, University of California San Francisco
  • Has Y90 Gone Cold for NETs? TARE Causes Long-Term Toxicity and Should be Reserved for 2nd-Line - Michael Soulen, MD, University of Pennsylvania
  • TARE Should Remain a 1st-Line Option for Liver Metastasis - Sharon Kwan, MD, MS, University of Washington
  • The Best of Both Worlds: Intra-Arterial PRRT - Arthur Braat, MD, PhD, University Medical Center Utrecht

4:00 – 4:20am: Break

4:20 – 5:20pm: Oberndorfer Cup Competition (NET Quiz)

5:20 – 5:45pm: NANETS Awards

6:00 – 7:30pm: Poster Session Reception

Saturday, October 6

7:00 – 8:00am: Breakfast with the Experts

  • Advanced Liver Surgery - Xavier Keutgen, MD, Rush University Medical Center; Eric Nakakura, MD, PhD, University of California, San Francisco; and Rod Pommier, MD, Oregon Health & Science University
  • Interesting Cases - Martyn Caplin, BSc Hons, DM, FRCP, Royal Free Hospital, United Kingdom
  • Workup of Abnormal Markers - Michelle Kim, MD, Mount Sinai Hospital
  • Endoscopic Management of pNETs - Nikhil Kumta, MD, MS, Mount Sinai Hospital
  • Endoscopic Management of Luminal NETS - Dermot O'Toole, MD, FRCPI, St. James Hospital and Trinity College

8:05 – 9:00am: Clinical Management 4 - Year in Review

  • New Lung NET Guidelines – NANETS/CommNETS - Sukhmani Padda, MD, Stanford University
  • New Trials and Exciting Developments - Thorvardur Halfdanarson, MD, Mayo Clinic
  • Appropriate Use Criteria for Ga68SR-PET - Thomas Hope, MD, University of California, San Francisco
  • Debate: Should PRRT Be Used in Bronchial NETs
    • No - Marianne Pavel, MD, Charite - Universitatsmedizin Berlin
    • Yes - Jonathan Strosberg, MD, Moffit Cancer Center

9:00 – 10:00am: Research Didactic Session

  • Spatial Systems Biomedicine - Joe Gray, PhD, Oregon Health & Science University
  • Merkell Cell Carcinoma - Paul Nghiem, MD, PhD, UW Medical Center at Lake Union
  • Role of Myc in NE Differentiation, Survival, Resistance in Pancreatic Cancer - Rosalie Sears, PhD, Oregon Health and Science University

10:00 – 10:30am: Break

10:30 – 11:30am: Clinical Management 5 - Patient-Centered Care

  • Measuring Patient-Centered Outcomes and the Patient Experience in NETs - Renuka Oyer, MD, Roswell Park Cancer Institute
  • Survivorship Issues in NETs - Janice Pasieka, MD, FRCSC, FACS, University of Calgary
  • Using Population-Based Data to Improve Patient Outcomes in NETs - Arvind Dasari, MD, MS, MD Anderson Cancer Center
  • Debate: Is Measuring CGA Routinely in the Best Interest of Our Patients?
    • No - Emily Bergsland, MD, University of California, San Francisco
    • Yes - Dermot O'Toole, MD, FRCPI, St. James Hospital and Trinity College

11:30 am – 12:30pm: Featured Abstracts 2 - Clinical Abstracts

  • A Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients with Advanced Pancreatic Neuroendocrine Tumors: A Trial of the ECOG-ACRIN Cancer Research Group (E2211) - Pamela L. Kunz, MD, Stanford University
  • The Cost-Effectiveness of Initial vs. Delayed Lanreotide for Treatment of Metastatic Enteropancreatic Neuroendocrine Tumors in the United States - James I. Barnes, MD, VA Palo Alto Health Care System
  • Surgery vs surveillance for well-differentiated pancreatic neuroendocrine tumors (Pan NETs): An eleven-year analysis of the National Cancer Data Base (NCDB) - Hussein Asi, University of Oklahoma
  • Clinical Outcomes in Patients with Baseline Renal Dysfunction in the NETTER-1 Study: 177Lu-DOTATATE vs. High Dose Octreotide in Progressive Midgut Neuroendocrine Tumors - Jonathan Strosberg, MD, Moffit Cancer Center
  • A Pilot Study of the Cyclin Dependent Kinases 4, 6 Inhibitor Ribociclib in Patients with Foregut Neuroendocrine Tumors - Arvind Dasari, MD, MD Anderson Cancer Center
  • Tumor Growth Pattern and Intratumoral Fibrosis as Prognostic Factors in Pancreatic Neuroendocrine Neoplasms - Deyali Chatterjee, MD, Washington University in St. Louis

12:30 – 2:00pm: Industry Supported Lunch Symposium

2:00 – 2:40pm: NANETS Annual Meeting

2:40 – 3:40pm: Tumor Board 2 - Advanced Disease

  • Case 1: Carcinoid With Synchronous Liver Metastasis - Michael Soulen, MD, University of Pennsylvania
  • Case 2: Gastric Carcinoid - Michelle Kim, MD, Mount Sinai Hospital
  • Case 3: Metastatic pNET
  • Gastrointestinal Panelist: Bryson Katona, MD, PhD, University of Pennsylvania
  • Interventional Oncologist Panelist: Nicolas Fidelman, MD, University of California, San Francisco
  • Surgical Oncologist Panelist: Venu Pillarisetty, MD, FACS, Seattle Cancer Care Alliance
  • Medical Oncologist Panelist: Kit Wong, MD, University of Washington

3:40 – 4:00pm: Closing Remarks